Word: biotech
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...spitting up their mother’s milk (then still-uncontaminated by transgenic proteins) the relationship of the University to for-profit biotechnology companies was the subject of somber faculty meetings and cautious pronouncements by former University President Derek C. Bok. Although the relationship between the faculty and the biotech industry is less strained than it once was, the problems of actually building companies has not gone away—and those problems illustrate why Summers’ comparison to the electronics industry that grew up around Stanford University is not just unhelpful, but absurd...
...payoffs are the biggest) has kept it a wild and unpredictable frontier. The journal Nature reported earlier this month that biotechnology stocks have collectively lost two-thirds of their value in the past two years. The University of California at San Francisco, which has forged close ties with the biotech industry in California, has seen collaborations with companies for research drop by nearly half from 2000. Such stark figures should give Summers pause before he starts intertwining Harvard research with the work of biotech companies. Indeed, Harvard has always been hesitant to associate itself too closely with for-profit companies...
...clearly say what definitions and regulations he’s talking about, or how the Silicon Valley model applies to the vastly different world of life sciences. But as the public’s confidence in corporations continues to fall with the Dow, the dream of Biotech Valley, Boston seems more and more like a project Harvard should leave...
...scandals hitting Wall Street, only ImClone's makes it into the society pages. But Martha Stewart is not the only stockholder of the biotech firm who is coming under suspicion for possible insider trading. Documents obtained by TIME show dumping of ImClone stocks by its executives that dwarfed Stewart's $228,000 sale. And their trading preceded Stewart's by weeks, starting just after Food and Drug Administration (FDA) officials met privately with an ImClone vice president last Dec. 4 and informally signaled there could be licensing problems for the company's cancer drug Erbitux. The FDA formally turned down...
...scandals hitting Wall Street, only ImClone's makes it into the society pages. But Martha Stewart is not the only stockholder of the biotech firm who is coming under suspicion for possible insider trading. Documents obtained by Time show dumping of ImClone stocks by its executives that dwarfed Stewart's $228,000 sale. And their trading preceded Stewart's by weeks, starting just after Food and Drug Administration (FDA) officials met privately with an ImClone vice president last Dec. 4 and informally signaled there could be licensing problems for the company's cancer drug Erbitux. The FDA formally turned down...